Annals of Oncology Advance Access originally published online on December 15, 2005
Annals of Oncology 2006 17(2):304-312; doi:10.1093/annonc/mdj072
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma
1 University of Pittsburgh School of Medicine, Starzl Transplantation Institute, Liver Cancer Center, Pittsburgh, PA; 2 Evanston Northwestern Healthcare and Northwestern University Feinberg School of Medicine, Chicago, IL, USA
* Correspondence to: Dr J. L. Steel, University of Pittsburgh, School of Medicine, Starzl Transplantation Institute, Liver Cancer Center, 3459 Fifth Avenue, Montefiore 7 South, Pittsburgh, PA 15213, USA. Tel: +1-412-692-2041; Fax: +1-412-692-2002; E-mail: steeljl{at}msx.upmc.edu
Background: To test the reliability, sensitivity to change in biomarkers associated with disease progression and response to treatment, and clinical meaningfulness of the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) in patients with hepatobiliary carcinoma.
Patients and methods: One hundred and fifty-eight patients diagnosed with hepatobiliary carcinoma were prospectively studied. Health-related quality of life (HRQL) was assessed at baseline (prior to treatment), 3-month follow-up (n = 55) and 6-month follow-up (n = 27).
Results: The internal consistency of all the scales of the FACT-Hep were adequate at all time points (>0.75). The FACT-Hep was found to be sensitive to changes in clinical indicators (alkaline phosphate, alpha-fetoprotein, hemoglobin and survival) that reflect disease progression and response to treatment. Combined results from distribution-based and cross-sectional anchor-based analyses provide the following minimally important difference (MID) estimates: FACT-General (FACT-G) subscales = 23; FACT-G = 67; Hepatobiliary Cancer Subscale = 56; FACT-Hep = 89; Trial Outcome Index = 78; and FACT-Hepatobiliary Symptom Index = 23 points.
Conclusions: The FACT-Hep is a reliable instrument that is responsive to clinical indicators of disease progression and response to treatment. The MID estimates can aid interpretation of HRQL data and facilitate sample size calculation in clinical trials.
Key words: clinical significance, Functional Assessment of Cancer Therapy-Hepatobiliary, health-related quality of life, hepatobiliary carcinoma, minimally important difference
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
F. J. Hlubocky, M. J. Ratain, M. Wen, and C. K. Daugherty Complementary and Alternative Medicine Among Advanced Cancer Patients Enrolled on Phase I Trials: A Study of Prognosis, Quality of Life, and Preferences for Decision Making J. Clin. Oncol., February 10, 2007; 25(5): 548 - 554. [Abstract] [Full Text] [PDF] |
||||
